Although PD-L1 expression, tumor mutation burden (TMB), IFNγ-related T-cell-inflated gene expression profile (8) and tumor immune dysfunction and exclusion (TIDE) (9) have been established, these biomarkers and transcriptomic signatures have only low predictive power in independent validation (10). The gene discussed is CD274; the disease is neoplasm.